Recrutamento encerrado
FASE
Número Europeu 2016-004740-11
MK-3475-522 KEYNOTE-522
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
Detalhes
Destaques